(Source: NCI - National Cancer Institute) NCI Press Release Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer Patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard treatment who received the drug bevacizumab (Avastin) lived 3.7 months longer than patients who did not receive the drug, according to an interim analysis of a large, randomized clinical trial. The clinical trial, known as GOG240, was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Gynecological Oncology Group (GOG). Genentech,...
0 Responses to Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer (NCI - National Cancer Institute)